340B Oversight Gathering Steam In Senate; HELP Committee Plans Hearing
Executive Summary
With several pieces of legislation in play that could overhaul 340B transparency and oversight, hospitals and sponsors will have a lot on the line during Senate hearing planned for 'early spring.'
You may also be interested in...
340B Provider Reforms Gaining Momentum In Congress
House Energy & Commerce Committee recommends more oversight of hospital participation in the 340B drug discount program.
FDA’s Real-World Evidence Project Finds That Pragmatic Clinical Trials Are Easier To DUPLICATE
Results from the US Food and Drug Administration’s RCT DUPLICATE demonstration are in. The findings both legitimize certain real-world evidence studies and also highlight the challenges involved in using RWE to replicate randomized clinical trials.
Preapproval Information Exchange Between Sponsors, Insurers Clarified In House User Fee Bill
By codifying FDA guidance, pending legislation aims to encourage industry to become more comfortable with even unsolicited communications to payers about investigational drugs.